A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation

References

• Eliopoulos AG. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004;4:360–11. PMID: 15251129. doi:10.1016/j.coph.2004.02.008.
   PubMed Web of Science ®Google Scholar
• Monteran L, Erez N. The dark side of fibroblasts: cancer-associated fibroblasts as mediators of immunosuppression in the tumor microenvironment. Front Immunol. 2019;10:1835. PMID: 31428105. doi:10.3389/fimmu.2019.01835.
   PubMed Web of Science ®Google Scholar
• Richards DM, Sefrin JP, Gieffers C, Hill O, Merz C. Concepts for agonistic targeting of CD40 in immuno-oncology. Hum Vaccin Immunother. 2020;16:377–87. PMID: 31403344. doi:10.1080/21645515.2019.1653744.
   PubMed Web of Science ®Google Scholar
• Liu L, Wu Y, Ye K, Cai M, Zhuang G, Wang J. Antibody-targeted TNFRSF activation for cancer immunotherapy: the role of fcgammariib cross-linking. Front Pharmacol. 2022;13:924197. PMID: 35865955. doi:10.3389/fphar.2022.924197.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017;17:175–86. PMID: 27927088. doi:10.1080/14737140.2017.1270208.
   PubMed Web of Science ®Google Scholar
• Rossetti RAM, Lorenzi NPC, Yokochi K, Rosa M, Benevides L, Margarido PFR, Baracat EC, Carvalho JP, Villa LL, Lepique AP, et al. B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses. Plos One. 2018;13:e0199034. PMID: 29975708. doi:10.1371/journal.pone.0199034.
   PubMed Web of Science ®Google Scholar
• Huffman AP, Lin JH, Kim SI, Byrne KT, Vonderheide RH. CCL5 mediates CD40-driven CD4+ T cell tumor infiltration and immunity. JCI Insight. 2020;5: PMID: 32324594. doi:10.1172/jci.insight.137263.
   PubMed Web of Science ®Google Scholar
• Enell Smith K, Deronic A, Hagerbrand K, Norlen P, Ellmark P. Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy. Expert Opin Biol Ther. 2021;21:1635–46. PMID: 34043482. doi:10.1080/14712598.2021.1934446.
   PubMed Web of Science ®Google Scholar
• Salomon R, Dahan R. Next generation CD40 agonistic antibodies for cancer immunotherapy. Front Immunol. 2022;13:940674. PMID: 35911742. doi:10.3389/fimmu.2022.940674.
   PubMed Web of Science ®Google Scholar
• White AL, Chan HT, French RR, Willoughby J, Mockridge CI, Roghanian A, Penfold CA, Booth SG, Dodhy A, Polak ME, et al. Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. Cancer Cell. 2015;27:138–48. PMID: 25500122. doi:10.1016/j.ccell.2014.11.001.
   PubMed Web of Science ®Google Scholar
• Filbert EL, Bjorck PK, Srivastava MK, Bahjat FR, Yang X. APX005M, aCD40 agonist antibody with unique epitope specificity and Fc receptor binding profile for optimal therapeutic application. Cancer Immunol Immunother. 2021;70:1853–65. PMID: 33392713. doi:10.1007/s00262-020-02814-2.
   PubMed Web of Science ®Google Scholar
• Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Totterman TH, Mangsbo SM. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer. Cancer Immunol Res. 2014;2:80–90. PMID: 24778163. doi:10.1158/2326-6066.CIR-13-0067.
   PubMed Web of Science ®Google Scholar
• Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011;17:2270–80. PMID: 21389097. doi:10.1158/1078-0432.CCR-10-2888.
   PubMed Web of Science ®Google Scholar
• Irenaeus SMM, Nielsen D, Ellmark P, Yachnin J, Deronic A, Nilsson A, Norlen P, Veitonmaki N, Wennersten CS, Ullenhag GJ. First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies. Int J Cancer. 2019;145:1189–99. PMID: 30664811. doi:10.1002/ijc.32141.
   PubMed Web of Science ®Google Scholar
• Hagerbrand K, Varas L, Deronic A, Nyesiga B, Sundstedt A, Ljung L, Sakellariou C, Werchau D, Thagesson M, Gomez Jimenez D, et al. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies. J Immuno Ther Cancer. 2022;10:e005018. PMID: 36323431. doi:10.1136/jitc-2022-005018.
   PubMed Web of Science ®Google Scholar
• Sum E, Rapp M, Frobel P, Le Clech M, Durr H, Giusti AM, Perro M, Speziale D, Kunz L, Menietti E, et al. Fibroblast activation protein alpha-targeted CD40 agonism abrogates systemic toxicity and enables administration of high doses to induce effective antitumor immunity. Clin Cancer Res. 2021;27:4036–53. PMID: 33771854. doi:10.1158/1078-0432.CCR-20-4001.
   PubMed Web of Science ®Google Scholar
• Rigamonti N, Veitonmaki N, Domke C, Barsin S, Jetzer S, Abdelmotaleb O, Bessey R, Lekishvili T, Malvezzi F, Gachechiladze M, et al. A multispecific anti-CD40 DARPin construct induces tumor-selective CD40 activation and tumor regression. Cancer Immunol Res. 2022;10:626–40. PMID: 35319751. doi:10.1158/2326-6066.CIR-21-0553.
   PubMed Web of Science ®Google Scholar
• Paulsson J, Ehnman M, Ostman A. PDGF receptors in tumor biology: prognostic and predictive potential. Future Oncol. 2014;10:1695–708. PMID: 25145436. doi:10.2217/fon.14.83.
   PubMed Web of Science ®Google Scholar
• Ostman A. PDGF receptors in tumor stroma: biological effects and associations with prognosis and response to treatment. Adv Drug Deliv Rev. 2017;121:117–23. PMID: 28970051. doi:10.1016/j.addr.2017.09.022.
   PubMed Web of Science ®Google Scholar
• Heldin CH, Lennartsson J, Westermark B. Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis. J Intern Med. 2018;283:16–44. PMID: 28940884. doi:10.1111/joim.12690.
   PubMed Web of Science ®Google Scholar
• Strell C, Folkvaljon D, Holmberg E, Schiza A, Thurfjell V, Karlsson P, Bergh J, Bremer T, Akslen LA, Warnberg F, et al. High PDGFRb expression predicts resistance to radiotherapy in DCIS within the SweDCIS randomized trial. Clin Cancer Res. 2021;27:3469–77. PMID: 33952629. doi:10.1158/1078-0432.CCR-20-4300.
   PubMed Web of Science ®Google Scholar
• Strell C, Norberg KJ, Mezheyeuski A, Schnittert J, Kuninty PR, Moro CF, Paulsson J, Schultz NA, Calatayud D, Lohr JM, et al. Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC. Br J Cancer. 2017;117:65–77. PMID: 28524160. doi:10.1038/bjc.2017.140.
   PubMed Web of Science ®Google Scholar
• Strell C, Paulsson J, Jin SB, Tobin NP, Mezheyeuski A, Roswall P, Mutgan C, Mitsios N, Johansson H, Wickberg SM, et al. Impact of epithelial-stromal interactions on peritumoral fibroblasts in ductal carcinoma in situ. J Natl Cancer Inst. 2019;111:983–95. PMID: 30816935. doi:10.1093/jnci/djy234.
   PubMedGoogle Scholar
• Pellinen T, Paavolainen L, Martin-Bernabe A, Papatella Araujo R, Strell C, Mezheyeuski A, Backman M, La Fleur L, Bruck O, Sjolund J, et al. Fibroblast subsets in non-small cell lung cancer: associations with survival, mutations, and immune features. J Natl Cancer Inst. 2022;115:71–82. PMID: 36083003. doi:10.1093/jnci/djac178.
   Google Scholar
• Stahl S, Graslund T, Eriksson Karlstrom A, Frejd FY, Nygren PA, Lofblom J. Affibody molecules in biotechnological and medical applications. Trends Biotechnol. 2017;35:691–712. PMID: 28514998. doi:10.1016/j.tibtech.2017.04.007.
   PubMed Web of Science ®Google Scholar
• Frejd FY, Kim KT. Affibody molecules as engineered protein drugs. Experimental & Molecular Medicine. 2017;49:e306. PMID: 28336959. doi:10.1038/emm.2017.35.
   PubMed Web of Science ®Google Scholar
• Yu F, Gudmundsdotter L, Akal A, Gunneriusson E, Frejd F, Nygren PA. An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid a secretion in vivo. MAbs. 2014;6:1598–607. PMID: 25484067. doi:10.4161/mabs.36089.
   PubMed Web of Science ®Google Scholar
• Sorensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandstrom M, Lubberink M, Olofsson H, et al. Measuring HER2-receptor expression in metastatic breast cancer using [68Ga]ABY-025 Affibody PET/CT. Theranostics. 2016;6:262–71. PMID: 26877784. doi:10.7150/thno.13502.
   PubMed Web of Science ®Google Scholar
• Klint S. Izokibep – Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis. mAbs. press, 2023. doi:10.1080/19420862.2023.2209920.
   Google Scholar
• Lindborg M, Cortez E, Hoiden-Guthenberg I, Gunneriusson E, von Hage E, Syud F, Morrison M, Abrahmsen L, Herne N, Pietras K, et al. Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor beta in vivo. J Mol Biol. 2011;407:298–315. PMID: 21277312. doi:10.1016/j.jmb.2011.01.033.
   PubMed Web of Science ®Google Scholar
• Tolmachev V, Varasteh Z, Honarvar H, Hosseinimehr SJ, Eriksson O, Jonasson P, Frejd FY, Abrahmsen L, Orlova A. Imaging of platelet-derived growth factor receptor beta expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591. J Nucl Med. 2014;55:294–300. PMID: 24408895. doi:10.2967/jnumed.113.121814.
   PubMed Web of Science ®Google Scholar
• Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umana P, Mossner E. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel. 2016;29:457–66. PMID: 27578889. doi:10.1093/protein/gzw040.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Torigian DA, Chiorean EG, Saboury B, Brothers A, Alavi A, Troxel AB, Sun W, Teitelbaum UR, Vonderheide RH, et al. A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma. Clin Cancer Res. 2013;19:6286–95. PMID: 23983255. doi:10.1158/1078-0432.CCR-13-1320.
   PubMed Web of Science ®Google Scholar
• O’Hara MH, O’Reilly EM, Varadhachary G, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, Cabanski CR, et al. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. Lancet Oncol. 2021;22:118–31. PMID: 33387490. doi:10.1016/S1470-2045(20)30532-5.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH. CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med. 2020;71:47–58. PMID: 31412220. doi:10.1146/annurev-med-062518-045435.
   PubMed Web of Science ®Google Scholar
• Paulsson J, Ryden L, Strell C, Frings O, Tobin NP, Fornander T, Bergh J, Landberg G, Stal O, Ostman A. High expression of stromal PDGFRbeta is associated with reduced benefit of tamoxifen in breast cancer. J Pathol Clin Res. 2017;3:38–43. PMID: 28138400. doi:10.1002/cjp2.56.
   PubMedGoogle Scholar
• Kilvaer TK, Rakaee M, Hellevik T, Vik J, Petris L, Donnem T, Strell C, Ostman A, Busund LR, Martinez-Zubiaurre I. Differential prognostic impact of platelet-derived growth factor receptor expression in NSCLC. Sci Rep. 2019;9:10163. PMID: 31308421. doi:10.1038/s41598-019-46510-3.
   PubMed Web of Science ®Google Scholar
• Kurahara H, Maemura K, Mataki Y, Sakoda M, Shinchi H, Natsugoe S. Impact of p53 and PDGFR-beta expression on metastasis and prognosis of patients with pancreatic cancer. World J Surg. 2016;40:1977–84. PMID: 26940582. doi:10.1007/s00268-016-3477-2.
   PubMed Web of Science ®Google Scholar
• Hagglof C, Hammarsten P, Josefsson A, Stattin P, Paulsson J, Bergh A, Ostman A, Westermark P. Stromal PDGFRβ expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLos One. 2010;5:e10747. PMID: 20505768. doi:10.1371/journal.pone.0010747.
   PubMed Web of Science ®Google Scholar
• Paulsson J, Sjoblom T, Micke P, Ponten F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirstrom K, Ostman A. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am J Pathol. 2009;175:334–41. PMID: 19498003. doi:10.2353/ajpath.2009.081030.
   PubMed Web of Science ®Google Scholar
• Frodin M, Mezheyeuski A, Corvigno S, Harmenberg U, Sandstrom P, Egevad L, Johansson M, Ostman A. Perivascular PDGFR-beta is an independent marker for prognosis in renal cell carcinoma. Br J Cancer. 2017;116:195–201. PMID: 27931046. doi:10.1038/bjc.2016.407.
   PubMed Web of Science ®Google Scholar
• Corvigno S, Wisman GB, Mezheyeuski A, van der Zee AG, Nijman HW, Avall-Lundqvist E, Ostman A, Dahlstrand H, van der Zee AGJ. Markers of fibroblast-rich tumor stroma and perivascular cells in serous ovarian cancer: inter- and intra-patient heterogeneity and impact on survival. Oncotarget. 2016;7:18573–84. PMID: 26918345. doi:10.18632/oncotarget.7613.
   PubMedGoogle Scholar
• Moreno-Ruiz P, Corvigno S, Te Grootenhuis NC, La Fleur L, Backman M, Strell C, Mezheyeuski A, Hoelzlwimmer G, Klein C, Botling J, et al. Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation. Lung Cancer. 2021;155:10–19. PMID: 33706022. doi:10.1016/j.lungcan.2021.02.028
   PubMed Web of Science ®Google Scholar
• Tao Z, Liu Y, Yang H, Feng Y, Li H, Shi Q, Li S, Cheng J, Lu X. Customizing a Tridomain TRAIL variant to achieve active tumor homing and endogenous albumin-controlled release of the molecular machine in vivo. Biomacromolecules. 2020;21:4017–29. PMID: 32804484. doi:10.1021/acs.biomac.0c00785.
   PubMed Web of Science ®Google Scholar
• Tao Z, Yang H, Shi Q, Fan Q, Wan L, Lu X. Targeted delivery to tumor-associated pericytes via an Affibody with high Affinity for PDGFRbeta enhances the in vivo antitumor effects of human TRAIL. Theranostics. 2017;7:2261–76. PMID: 28740549. doi:10.7150/thno.19091.
   PubMed Web of Science ®Google Scholar
• Luke JJ, Barlesi F, Chung K, Tolcher AW, Kelly K, Hollebecque A, Le Tourneau C, Subbiah V, Tsai F, Kao S, et al. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J ImmunoTher Cancer. 2021;9:e002015. PMID: 33608377. doi:10.1136/jitc-2020-002015.
   PubMed Web of Science ®Google Scholar
• Volk AL, Mebrahtu A, Ko BK, Lundqvist M, Karlander M, Lee HJ, Frejd FY, Kim KT, Lee JS, Rockberg J. Bispecific antibody molecule inhibits tumor cell proliferation more efficiently than the two-molecule combination. Drugs RD. 2021;21:157–68. PMID: 33721246. doi:10.1007/s40268-021-00339-2.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yu G-L, Zhu W Anti-cd40 antibodies and methods of use. Patent WO2014070934A1. 2014.
   Google Scholar
• Fredriksson L, Ehnman M, Fieber C, Eriksson U. Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator. J Biol Chem. 2005;280:26856–62. PMID: 15911618. doi:10.1074/jbc.M503388200.
   PubMed Web of Science ®Google Scholar
• Nupponen NN, Paulsson J, Jeibmann A, Wrede B, Tanner M, Wolff JE, Paulus W, Ostman A, Hasselblatt M. Platelet-derived growth factor receptor expression and amplification in choroid plexus carcinomas. Mod Pathol. 2008;21:265–70. PMID: 18157090. doi:10.1038/modpathol.3800989.
   PubMed Web of Science ®Google Scholar